Measuring a blood marker against heart structure in hypertensive heart disease
Studies whether a blood level of miR-455-5p relates to heart structure and function in hypertension.
Plain-language title generated from the registry record
Registry title: Serum miR-455-5p and Cardiac Structure and Function Parameters in Patients With Hypertensive Heart Disease
Key facts
- Where
- Shenzhen, ChinaSee the site
Where in China
- the University of Hongkong-Shenzhen HospitalShenzhen, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The University of Hong Kong-Shenzhen Hospital
- Trial code
- NCT07033676
- Record updated
- 24 June 2025
- Original description
Hypertensive heart disease (HHD) is the leading cause of mortality and morbidity worldwide. In 2017, the prevalence of HHD worldwide was 217.9 per 100,000 people, an increase of 7.4% over 1990, which has brought huge financial burden and social and economic losses to the world. Therefore, HHD is a major public health challenge worldwide. In our previous studies, we found that miR-455-5p, a microRNA, could functioned as an inducer to promote cardiac hypertrophy. Because cardiac hypertrophy was a common phenomenon in patients with HHD, so it is interesting to clarify whether miR-455-5p could be employed as a marker to indicate the function and/or structure of heart in the development of HHD. Thus, the purpose of this study was to collect blood samples of hypertensive patients, as well as analysis the correlation between serum miR-455-5p level and cardiac function. The research could help doctors better predict the course of hypertensive heart disease and provide more effective treatments for different patients.Read full original descriptionShow less
Study on the Correlation Between Serum miR-455-5p Level and Cardiac Structure and Function Parameters in Patients With Hypertensive Heart Disease
Hypertensive heart disease (HHD) is the leading cause of mortality and morbidity worldwide. In 2017, the prevalence of HHD worldwide was 217.9 per 100,000 people, an increase of 7.4% over 1990, which has brought huge financial burden and social and economic losses to the world. Therefore, HHD is a major public health challenge worldwide. In our previous studies, we found that miR-455-5p, a microRNA, could functioned as an inducer to promote cardiac hypertrophy. Because cardiac hypertrophy was a common phenomenon in patients with HHD, so it is interesting to clarify whether miR-455-5p could be employed as a marker to indicate the function and/or structure of heart in the development of HHD. Thus, the purpose of this study was to collect blood samples of hypertensive patients, as well as analysis the correlation between serum miR-455-5p level and cardiac function. The research could help doctors better predict the course of hypertensive heart disease and provide more effective treatments for different patients.
Inclusion: 1. age ≥18 years; 2. male or female; 3. systolic blood pressure ≥140mmHg or (and) diastolic blood pressure > 90mmHg; 4. history of hypertension>1year, NYHA grade I-IV.
Exclusion: hypertensive heart diseases patients with other metabolic diseases or congenital diseases were excluded from the study.